/IDRSF

IDRSF Stock - Idorsia Ltd

Q: What is the analyst price target for IDRSF?

Analyst price target information is not currently available for IDRSF.

Q: What is IDRSF's market cap?

Market capitalization information is not currently available for IDRSF.

Healthcare|Biotechnology|OTC

$4.80-3.03%

$0.15 (-3.03%) • Dec 19

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $5.28

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for IDRSF

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta1.70

52W High$5.82

52W Low$0.70

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	$112.51M	$152.39M	$97.10M	$35.35M	$71.76M
Gross Profit	$76.58M	$145.24M	$90.84M	$17.32M	$-309,318,000
Gross Margin	68.1%	95.3%	93.5%	49.0%	-431.1%
Operating Income	$-232,014,000	$-255,145,000	$-802,965,000	$-613,004,000	$-410,582,000
Net Income	$-263,757,000	$-297,921,000	$-827,896,000	$-634,595,000	$-444,791,000
Net Margin	-234.4%	-195.5%	-852.6%	-1795.2%	-619.8%
EPS	$-1.45	$-1.67	$-4.67	$-3.77	$-3.11

Company Overview

Idorsia Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Idorsia Ltd has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; license agreement with Mochida Pharmaceutical for the supply, co-development, and comarketing of daridorexant; and Hoffman-La Roche Inc. to develop and market compounds in the field of cancer immunotherapy. It also has a collaboration with Antares Pharma, Inc. for the development of a self- administered drug device product for Selatogrel; and Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is in Phase II clinical trial for the treatment of epilepsy. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland.

Visit Website

Rating Distribution

Strong Buy

Buy / Outperform

20%

Hold / Neutral

60%

Sell / Underperform

20%

Analyst Consensus🔴 Bearish

1 Bullish4 Neutral/Bearish

Price Targets

No price targets available

Recent Analyst Actions

Date	Firm	Action	Rating	Price Target
September 15th 2025	H.C. Wainwright	Upgrade	Buy	-
June 22nd 2023	Morgan Stanley	Resumed	Underweight	-
April 26th 2023	Credit Suisse	Downgrade	Underperform	-
January 18th 2023	Jefferies	Downgrade	Hold	-
November 10th 2022	Credit Suisse	Downgrade	Neutral	-
October 21st 2022	Deutsche Bank	Downgrade	Hold	-

Earnings History & Surprises

IDRSF

Beat Rate

56%

Last 18 quarters

Avg Surprise

+26.6%

EPS vs Estimate

Beats / Misses

10/6

2 met exactly

Latest EPS

$-0.35

Q4 2025

EPS Surprise History

Q1 24

+15.9%

$-0.76vs$-0.91

Q2 24

-24.9%

$0.14vs$0.19

Q3 24

-65.9%

$-0.67vs$-0.41

Q4 24

+0.6%

$-0.62vs$-0.63

Q1 25

+20.3%

$-0.49vs$-0.62

Q2 25

+234.0%

$0.39vs$-0.29

Q3 25

+69.8%

$-0.08vs$-0.25

Q4 25

-25.0%

$-0.35vs$-0.28

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q2 2026	Apr 28, 2026	—	—	—	—
Q1 2026	Feb 25, 2026	—	—	—	—
Q4 2025	Oct 30, 2025	$-0.28	$-0.35	-25.0%	✗ MISS
Q3 2025	Jul 30, 2025	$-0.25	$-0.08	+69.8%	✓ BEAT
Q2 2025	Apr 30, 2025	$-0.29	$0.39	+234.0%	✓ BEAT
Q1 2025	Mar 4, 2025	$-0.62	$-0.49	+20.3%	✓ BEAT
Q4 2024	Oct 29, 2024	$-0.63	$-0.62	+0.6%	✓ BEAT
Q3 2024	Jul 25, 2024	$-0.41	$-0.67	-65.9%	✗ MISS
Q2 2024	May 21, 2024	$0.19	$0.14	-24.9%	✗ MISS
Q1 2024	Mar 20, 2024	$-0.91	$-0.76	+15.9%	✓ BEAT
Q3 2023	Sep 30, 2023	$-1.06	$1.37	+229.5%	✓ BEAT
Q2 2023	Jun 30, 2023	$-1.07	$-1.21	-13.2%	✗ MISS
Q1 2023	Mar 31, 2023	$-1.17	$-1.30	-10.9%	✗ MISS
Q1 2023	Feb 7, 2023	$-1.34	$-1.09	+18.7%	✓ BEAT
Q4 2022	Oct 25, 2022	$-1.22	$-1.22	0.0%	= MET
Q3 2022	Jul 26, 2022	$-1.24	$-1.24	0.0%	= MET
Q2 2022	Apr 26, 2022	$-1.14	$-1.12	+1.8%	✓ BEAT
Q1 2022	Feb 8, 2022	$-1.30	$-1.32	-1.5%	✗ MISS
Q4 2021	Oct 25, 2021	$-1.06	$-0.83	+21.7%	✓ BEAT
Q3 2021	Jul 27, 2021	$-0.91	$-0.83	+8.8%	✓ BEAT